Difference between revisions of "Malignant solid neoplasm, EGFR-mutated"
Jump to navigation
Jump to search
m |
m (→References) |
||
| Line 34: | Line 34: | ||
[[Category:EGFR regimens]] | [[Category:EGFR regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
| + | [[Category:Site-agnostic regimens]] | ||
Revision as of 23:44, 5 April 2018
1 regimens on this page
1 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Erlotinib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hainsworth et al. 2018 (MyPathway) | Phase IIa, <20 pts in this arm |
Eligibility criteria
- EGFR nonsynonymous exon 18 or exon 21 mutations, or exon 19 deletions
Chemotherapy
- Erlotinib (Tarceva) 150 mg PO once per day
Continued until progression or intolerance
References
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed